Cargando…

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas

PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollring, Michael M., Werner, Jan-Michael, Ceccon, Garry, Lohmann, Philipp, Filss, Christian P., Fink, Gereon R., Langen, Karl-Josef, Galldiks, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227162/
https://www.ncbi.nlm.nih.gov/pubmed/36577872
http://dx.doi.org/10.1007/s11060-022-04218-x
_version_ 1785050710289678336
author Wollring, Michael M.
Werner, Jan-Michael
Ceccon, Garry
Lohmann, Philipp
Filss, Christian P.
Fink, Gereon R.
Langen, Karl-Josef
Galldiks, Norbert
author_facet Wollring, Michael M.
Werner, Jan-Michael
Ceccon, Garry
Lohmann, Philipp
Filss, Christian P.
Fink, Gereon R.
Langen, Karl-Josef
Galldiks, Norbert
author_sort Wollring, Michael M.
collection PubMed
description PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as grade 2 according to the World Health Organization classification of Central Nervous System tumors. Major diagnostic challenges in this situation are differential diagnosis, target definition for diagnostic biopsies, delineation of glioma extent for treatment planning, differentiation of treatment-related changes from tumor progression, and the evaluation of response to alkylating agents. The main focus of this review is the role of amino acid PET in this setting. Furthermore, in light of clinical trials using IDH inhibitors targeting the mutated IDH enzyme for treating patients with IDH-mutant gliomas, we also aim to give an outlook on PET probes specifically targeting the IDH mutation, which appear potentially helpful for response assessment.
format Online
Article
Text
id pubmed-10227162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-102271622023-05-31 Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas Wollring, Michael M. Werner, Jan-Michael Ceccon, Garry Lohmann, Philipp Filss, Christian P. Fink, Gereon R. Langen, Karl-Josef Galldiks, Norbert J Neurooncol Review PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as grade 2 according to the World Health Organization classification of Central Nervous System tumors. Major diagnostic challenges in this situation are differential diagnosis, target definition for diagnostic biopsies, delineation of glioma extent for treatment planning, differentiation of treatment-related changes from tumor progression, and the evaluation of response to alkylating agents. The main focus of this review is the role of amino acid PET in this setting. Furthermore, in light of clinical trials using IDH inhibitors targeting the mutated IDH enzyme for treating patients with IDH-mutant gliomas, we also aim to give an outlook on PET probes specifically targeting the IDH mutation, which appear potentially helpful for response assessment. Springer US 2022-12-29 2023 /pmc/articles/PMC10227162/ /pubmed/36577872 http://dx.doi.org/10.1007/s11060-022-04218-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Wollring, Michael M.
Werner, Jan-Michael
Ceccon, Garry
Lohmann, Philipp
Filss, Christian P.
Fink, Gereon R.
Langen, Karl-Josef
Galldiks, Norbert
Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
title Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
title_full Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
title_fullStr Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
title_full_unstemmed Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
title_short Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
title_sort clinical applications and prospects of pet imaging in patients with idh-mutant gliomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227162/
https://www.ncbi.nlm.nih.gov/pubmed/36577872
http://dx.doi.org/10.1007/s11060-022-04218-x
work_keys_str_mv AT wollringmichaelm clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT wernerjanmichael clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT ceccongarry clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT lohmannphilipp clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT filsschristianp clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT finkgereonr clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT langenkarljosef clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas
AT galldiksnorbert clinicalapplicationsandprospectsofpetimaginginpatientswithidhmutantgliomas